Seminal vesicles

United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Surgery, Health, Genetics, Oncology, Liquid biopsy, Neoplasm, Nucleic acid thermodynamics, FDA, Urine, Breast cancer, CGP, NTRK, Prostate cancer, NIH, Woman, Blood, Entrectinib, Seminal vesicles, Gene, Liquid, Health care, Research, Plasma, Chinese, NGS, DNA, Lung, Incidence, Patient, Circulating tumor DNA, Diagnosis, Illumina, Inc., Biomarker, DCIS, NSCLC, Medical imaging

The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032.
  • These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market.
  • Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market.

Feinstein Institutes’ Daniel A. Grande Named President-Elect of the International Cartilage Regeneration & Joint Preservation Society (ICRS)

Retrieved on: 
Thursday, April 18, 2024
Health, Hospitals, Other Health, Other Science, General Health, Research, Science, Education, FDA, Rheumatology, EVS, Microsoft Exchange Server, Intervertebral disc, Regenerative medicine, Seminal vesicles, Cartilage, Doctor of Philosophy, B cell, Meniscus, ICRS, Patient, Tissue engineering, Molecular medicine, 3D bioprinting, Medical research, Microsoft Access, Multimedia, Regeneration, Stem cell, Credit, Journal, Medical device

The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.

Key Points: 
  • The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.
  • View the full release here: https://www.businesswire.com/news/home/20240418363701/en/
    Feinstein Institutes’ Dr. Daniel A. Grande has been named the new president-elect of International Cartilage Repair Society.
  • (Credit: Feinstein Institutes)
    Dr. Grande, renowned for his significant contributions to cartilage repair and regeneration, will lead the ICRS in its mission to advance science and education in preventing and treating cartilage injuries.
  • "I am honored and excited to serve as the President-Elect of the International Cartilage Regeneration & Joint Preservation Society.

Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board

Retrieved on: 
Wednesday, April 10, 2024
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Breast cancer, Science Publishing Group, Immortalised cell line, University, International Society, ISAC, Jonni, SAB, CRISPR, Cell biology, Hospital, Seminal vesicles, Medical laboratory, Doctor of Philosophy, Pathology, Protein engineering, Therapy, New York Blood Center, Chairperson, Synthetic biology, Cardiovascular disease, Malignancy, Assistant, Inc., NX, HIV, Biomarker, Associate, SICS, AAPS, Flow cytometry

Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).

Key Points: 
  • Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).
  • The Nodexus SAB is chaired by Professor Jonni Moore, PhD, one of the world’s leading experts in flow cytometry, laboratory medicine, and cellular immunology.
  • He is a founding member of the Southern California Flow Cytometry Association (SoCal Flow) and the American Association of Pharmaceutical Scientists (AAPS) PharmaFlow Working Group.
  • “I’m extremely pleased to serve as the Chairperson of Nodexus’ Scientific Advisory Board,” said Dr. Moore.

Kytopen Announces Launch of Technology Access Program Supported by an Expanded Applications Team

Retrieved on: 
Tuesday, March 26, 2024
MED, Seminal vesicles, Research, Business development, TAP, MSC, CRISPR, Safety, Therapy

and DENVER, March 26, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, announces the launch of the Flowfect® Technology Access Program ("TAP") for early access to partners.

Key Points: 
  • and DENVER, March 26, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, announces the launch of the Flowfect® Technology Access Program ("TAP") for early access to partners.
  • "The Kytopen team is excited and proud to launch our Technology Access Program.
  • Earlier this year, Kytopen significantly expanded its process development and applications team with the hiring of researchers formerly from Artisan Bio, a developer of novel CRISPR editing systems and cell therapies, to support the incoming Technology Access Program partners and development of templated manufacturing processes for emerging non-viral applications.
  • Please reach out to [email protected] to request more information on the Flowfect® Technology Access Program.

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

Retrieved on: 
Friday, March 1, 2024
EVS, Therapy, Aegle, Harvard Medical School, Exosome, NRX, AbbVie, Quality, University, Conference, Patient, Development, Seminal vesicles, CMC, Medical device

Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."

Key Points: 
  • Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."
  • Dr. Sarel joins a prestigious lineup of speakers including representatives from leading exosome companies, e.g.
  • The summit will take place on April 23-25, 2024 in Boston, MA.
  • To learn more about the summit and to register, please visit the Conference Website .

NurExone’s Intellectual Property Portfolio Expands

Retrieved on: 
Tuesday, February 20, 2024
EVS, EV, Exosome, 3D, NRX, PCT, Cell, B cell, RNA, Patent, 3D bioprinting, IP, Intellectual property, Seminal vesicles, Fine chemical

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.
  • NurExone’s Intellectual property portfolio describes the ExoTherapy platform’s comprehensive technology and processes for the production of nanodrugs including large scale production of exosomes, loading of active molecules and the composition of the exosomes themselves.
  • The loading technology was presented to the public in the press release of February 12, 2024.
  • Aspects of the company’s platform which relate to Extracellular Vesicles (EVs) production are described in a growing intellectual property portfolio with two PCT applications currently in National Phases.

New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood

Retrieved on: 
Tuesday, March 5, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, General Health, Other Science, Science, Traffic barrier, EV, System, Blood, Cerebrospinal fluid, Neurological disorder, AUC, Amplification, Conference, Seminal vesicles, Biomarker, Patient, Dementia, DSM-IV codes, CSF, Disease, Diagnosis, PET, APEX, Brain, Medical imaging

The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.

Key Points: 
  • The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.
  • “These results provide further evidence that the APEX platform has the potential to offer highly sensitive and accurate Alzheimer’s disease diagnosis equivalent to PET scans from a simple blood draw,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • The APEX Aβ test is a blood-based diagnostic that uniquely detects very low levels of disease-specific proteins in blood with high accuracy.
  • EV-associated Aβ in blood are highly correlative and a direct reflection of Aβ build-up in the brain, a key abnormality in Alzheimer’s disease.

NurExone Launches Licensing Efforts for ExoTherapy Platform

Retrieved on: 
Wednesday, February 14, 2024
EVS, Messenger, Plasma protein binding, Exosome, NRX, PCT, Cell, Seminal vesicles, RNA, Patent, Patient, Listeria monocytogenes non-coding RNA, MicroRNA, Carbohydrate, Small RNA, Tissue, Environment, Fine chemical

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
  • The Company’s ExoTherapy platform for exosome-based therapy production includes: (i) large-scale exosome production using the Company’s dedicated bioreactor, (ii) synthesis of therapeutic cargo and (iii) processes to load the therapeutic cargo, creating nanodrugs.
  • Dr. Lior Shaltiel, CEO of NurExone, commented, “Exosomes have the potential to be the ultimate drug delivery system.
  • ExoPTEN, for patients with acute spinal cord injuries, is being developed on our platform, and we expect great success through licensing our technology for other indications!”.

IMCAS 2024: Rion Aesthetics’ CEO, Alisa Lask, to Unveil Cutting-Edge Platelet-Derived Exosome Technology Insights

Retrieved on: 
Thursday, February 1, 2024
Cosmetics, Retail, Other Health, Other Consumer, Women, Seniors, Baby Boomers, Other Retail, Fitness & Nutrition, Specialty, Vitamins, Supplements, Science, Other Science, Consumer, Research, Health, Multimedia, Seminal vesicles, La Tribune, Skin, Aesthetics, Exosome, Movement

Rion Aesthetics, a trailblazer in regenerative aesthetics, announced today that its internationally-recognized CEO, Alisa Lask, will present at the illustrious International Master Course on Aging Science (IMCAS) meeting in Paris.

Key Points: 
  • Rion Aesthetics, a trailblazer in regenerative aesthetics, announced today that its internationally-recognized CEO, Alisa Lask, will present at the illustrious International Master Course on Aging Science (IMCAS) meeting in Paris.
  • View the full release here: https://www.businesswire.com/news/home/20240201151491/en/
    Alisa Lask, CEO of Rion Aesthetics, with a diverse background in medical devices, pharmaceuticals, and skincare markets, stands at the forefront of revolutionizing the regenerative aesthetics industry.
  • (Photo: Business Wire)
    We stand at a pivotal moment in the evolution of regenerative aesthetics," said Alisa Lask.
  • Leading this transformative movement is Alisa Lask, whose expertise and vision at Rion Aesthetics have been critical in exploring the potential of exosomes.

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

Retrieved on: 
Thursday, January 25, 2024
Research, Stem cell, ALS, Health, Collaboration, Biotechnology, Partnership, Mitochondrion, Seminal vesicles, Injury, Alzheimer's disease, Uppsala University, Parkinson's disease, Pharmaceutical industry

This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.

Key Points: 
  • This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.
  • Karl-Henrik Grinnemo and Sergey Rodin of Uppsala University, vital contributors to this research, described the study as a "milestone in mitochondrial science."
  • "The partnership with Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation has been instrumental in this discovery, reflecting our collective commitment to pioneering medical solutions," he stated.
  • This collaborative effort represents a major addition to MitoSense Inc.'s achievements, highlighting the company's crucial role in advancing medical science and enhancing patient care.